A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.

Abstract:

OBJECTIVES:To compare the safety and efficacy of amprenavir [APV/j Agenerase trade mark; GlaxoSmithKline, [Ware, UK; 600 mg twice a day (bid)] boosted with low-dose ritonavir (RTV, 100 mg bid) with those of other protease inhibitors (PIs) in PI-experienced HIV-infected patients. STUDY DESIGN:Parallel-group, randomized, open-label, multicentre study. METHODS:One hundred and sixty-three patients with HIV predicted to be sensitive to APV, another PI and a nucleoside reverse transcriptase inhibitor (NRTI) were randomly assigned to receive either APV boosted with low-dose RTV (APV/r) or a standard of care (SOC) PI with or without low-dose RTV. The non-inferiority of APV/r to the SOC PIs was assessed by time-weighted average change from baseline (AAUCMB) in plasma viral load (vRNA) at week 16. RESULTS:The antiviral response for APV/r bid was non-inferior to that for the SOC PI group: the vRNA AAUCMB mean treatment difference was 0.043 log(10) HIV-1 RNA copies/mL [95% confidence interval (CI)-0.250, 0.335]. APV/r bid was generally well tolerated. CONCLUSIONS:Results confirm the antiviral activity, short-term safety and tolerability of APV/r bid in PI-experienced patients.

journal_name

HIV Med

journal_title

HIV medicine

authors

Pulido F,Katlama C,Marquez M,Thomas R,Clumeck N,Pedro Rde J,Cattelan AM,Zhu C,Tymkewycz P

doi

10.1111/j.1468-1293.2004.00224.x

keywords:

subject

Has Abstract

pub_date

2004-07-01 00:00:00

pages

296-302

issue

4

eissn

1464-2662

issn

1468-1293

pii

HIV224

journal_volume

5

pub_type

临床试验,杂志文章,多中心研究,随机对照试验
  • Euthanasia: from the perspective of HIV infected persons in Europe.

    abstract:BACKGROUND:In the debate about legalization of euthanasia very little attention has so far been given to the opinion of the patient. OBJECTIVE:To assess the opinion of persons with HIV infection in Europe. METHODS:A cross-sectional survey of persons with HIV infection attending HIV/AIDS treatment centres or HIV suppo...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1468-1293.2001.00053.x

    authors: Andraghetti R,Foran S,Colebunders R,Tomlinson D,Vyras P,Borleffs CJ,Fleerackers Y,Schrooten W,Borchert M

    更新日期:2001-01-01 00:00:00

  • Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.

    abstract:OBJECTIVES:The aims of the present study were to estimate the prevalence of renal impairment (RI) among HIV-infected adult patients and to investigate the associated factors. METHODS:A cross-sectional survey was conducted in a French hospital-based cohort. Clearance of creatinine (CC) was calculated using the Cockcrof...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2009.00780.x

    authors: Déti EK,Thiébaut R,Bonnet F,Lawson-Ayayi S,Dupon M,Neau D,Pellegrin JL,Malvy D,Tchamgoué S,Dabis F,Morlat P,Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

    更新日期:2010-05-01 00:00:00

  • Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.

    abstract:OBJECTIVES:Apricitabine (ATC) is a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor (NRTI) with significant antiviral activity in vitro, including activity against HIV-1 with reverse transcriptase mutations that confer resistance to other NRTIs. ATC has shown promising antiviral activity and good...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2010.00887.x

    authors: Cahn P,Altclas J,Martins M,Losso M,Cassetti I,Cooper DA,Cox S

    更新日期:2011-07-01 00:00:00

  • Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.

    abstract:OBJECTIVES:The aim of the study was to describe growth and body composition changes in HIV-positive children after they had initiated or changed antiretroviral therapy (ART) and to correlate these with viral, immune and treatment parameters. METHODS:Ninety-seven prepubertal HIV-positive children were observed over 48 ...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2010.00823.x

    authors: Chantry CJ,Cervia JS,Hughes MD,Alvero C,Hodge J,Borum P,Moye J Jr,PACTG 1010 Team.

    更新日期:2010-10-01 00:00:00

  • Risk factors for death among patients in French Guiana: 1996-2005.

    abstract::Risk factors for death in an HIV-infected cohort in French Guiana were studied in 1374 patients between 1996 and 2005. Of these patients, 48.5% were male and 76% were immigrants. Covariates were measured at the time of consultation. There were 223 deaths. Addictions [adjusted hazard ratio (HR)=13; 95% confidence inter...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2007.00492.x

    authors: Nacher M,Huber F,El Guedj M,Vaz T,Magnien C,Djossou F,Randrianjohany A,Alvarez F,Couppié P

    更新日期:2007-10-01 00:00:00

  • Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis.

    abstract::Despite advances in the treatment of HIV disease, the incidence and mortality of invasive cryptococcal disease remain significant. A matched, case-control study was performed to examine the impact of highly active antiretroviral therapy (HAART) and azole use on the incidence of invasive cryptococcal disease in HIV-inf...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2005.00289.x

    authors: Cantey PT,Stephens DS,Rimland D

    更新日期:2005-07-01 00:00:00

  • Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.

    abstract:OBJECTIVES:Conflicting results have been reported regarding the ability of valproic acid (VPA) to reduce the size of HIV reservoirs in patients receiving suppressive highly active antiretroviral therapy (HAART). In a randomized multicentre, cross-over study, we assessed whether adding VPA to stable HAART could potentia...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2011.00975.x

    authors: Routy JP,Tremblay CL,Angel JB,Trottier B,Rouleau D,Baril JG,Harris M,Trottier S,Singer J,Chomont N,Sékaly RP,Boulassel MR

    更新日期:2012-05-01 00:00:00

  • HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.

    abstract::The advent of potent highly active antiretroviral therapy (HAART) for persons infected with HIV-1 has led to a "new" chronic disease with complications including cardiovascular disease (CVD). CVD is a significant cause of morbidity and mortality in persons with HIV infection. In addition to traditional risk factors su...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1111/hiv.12346

    authors: Lambert CT,Sandesara PB,Hirsh B,Shaw LJ,Lewis W,Quyyumi AA,Schinazi RF,Post WS,Sperling L

    更新日期:2016-06-01 00:00:00

  • HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care?

    abstract:OBJECTIVES:In the UK, free HIV care is provided through dedicated HIV clinics. Using the national cohort of men who have sex with men (MSM) with diagnosed HIV infection and estimates of the number of undiagnosed men, we assessed whether high retention in HIV care and treatment coverage is sufficient to reduce HIV trans...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12066

    authors: Brown AE,Gill ON,Delpech VC

    更新日期:2013-10-01 00:00:00

  • Diagnosing HIV infection in patients presenting with glandular fever-like illness in primary care: are we missing primary HIV infection?

    abstract:OBJECTIVES:The aim of the study was to examine the prevalence of HIV infection in patients presenting in primary care with glandular fever (GF)-like illness. METHODS:Samples from primary care submitted for a GF screen between April 2009 and June 2010 were identified. Samples without an HIV request were anonymized and ...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2012.01023.x

    authors: Hsu DT,Ruf M,O'Shea S,Costelloe S,Peck J,Tong CY

    更新日期:2013-01-01 00:00:00

  • Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients.

    abstract:OBJECTIVE:As a proactive diagnosis of diabetes mellitus (DM) may prevent the onset of severe complications, we used an oral glucose tolerance test (OGTT) to check for impaired glucose tolerance (IGT) and DM in patients with long-standing HIV infection and long durations of exposure to antiretroviral drugs with normal f...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2010.00860.x

    authors: Gianotti N,Visco F,Galli L,Barda B,Piatti P,Salpietro S,Bigoloni A,Vinci C,Nozza S,Gallotta G,Lazzarin A,Castagna A

    更新日期:2011-02-01 00:00:00

  • National review of maternity care for women with HIV infection.

    abstract:OBJECTIVE:To assess adherence to the British HIV Association (BHIVA) 2001 guidelines for the management of HIV-infected pregnant women. METHODS:A survey and a case note review were carried out using structured questionnaires sent to providers of adult HIV care in the UK and Ireland. Participants were women with HIV in...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2006.00385.x

    authors: McDonald C,Curtis H,de Ruiter A,Johnson MA,Welch J,British HIV Association (BHIVA) and the BHIVA audit subcommittee.

    更新日期:2006-07-01 00:00:00

  • Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal.

    abstract:OBJECTIVES:The World Health Organization (WHO) recommends screening HIV-infected people for cryptococcal antigens to identify cryptococcosis, a major cause of AIDS-related deaths. As the burden of cryptococcosis is unknown in South Africa's KwaZulu-Natal province, we assessed the cryptococcal antigenuria prevalence amo...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12263

    authors: Drain PK,Kleene JM,Coleman SM,Losina E,Katz JN,Giddy J,Ross D,Freedberg KA,Bassett IV

    更新日期:2015-11-01 00:00:00

  • The case for indicator condition-guided HIV screening.

    abstract::One-half of the estimated 2.5 million people who now live with HIV in the World Health Organization (WHO) European Region are still diagnosed late. A central question is which clinical scenarios should trigger an HIV test recommendation in order to avoid late presentation. Drawing on the work of the HIV Indicator Dise...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12022

    authors: Lazarus JV,Hoekstra M,Raben D,Delpech V,Coenen T,Lundgren JD,HIV in Europe Initiative Steering Committee.

    更新日期:2013-08-01 00:00:00

  • Is PEP prescribed appropriately?

    abstract::We describe the characteristics of HIV post-exposure prophylaxis (PEP) recipients and PEP indications at 56 Dean Street, a central London sexual health clinic. PEP was prescribed on 577 occasions. Most (97%) was given for unprotected anal intercourse. Over a fifth of exposures involved recreational drug use. Of the pa...

    journal_title:HIV medicine

    pub_type: 信件

    doi:10.1111/hiv.12275

    authors: Whitlock G,Nwokolo N,McOwan A

    更新日期:2015-09-01 00:00:00

  • A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial.

    abstract:OBJECTIVES:To assess the efficacy and safety of adefovir dipivoxil (ADV) added to stable background antiretroviral therapy (ART) in HIV-infected individuals with advanced HIV disease. METHODS:ADHOC was a randomized, double-blind, placebo-controlled, international multicentre trial. Three hundred and one individuals wi...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1468-1293.2002.00111.x

    authors: ADHOC International Steering Committee.

    更新日期:2002-10-01 00:00:00

  • The effect of engagement in an HIV/AIDS integrated health programme on plasma HIV-1 RNA suppression among HIV-positive people who use illicit drugs: a marginal structural modelling analysis.

    abstract:OBJECTIVES:HIV treatment-as-prevention campaigns emphasize early diagnosis and immediate access to care and antiretroviral therapy for HIV-positive individuals in order to increase levels of plasma HIV RNA viral load (VL) suppression. However, the possible role of harm reduction-based programmes in this objective has n...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12493

    authors: Ti L,Dong H,Kerr T,Turje RB,Parashar S,Min JE,Montaner J,Wood E,Milloy MJ

    更新日期:2017-09-01 00:00:00

  • Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.

    abstract:OBJECTIVE:Based on the short-term results of the AIDS Clinical Trials Group (ACTG) A5095 trial, zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) is no longer recommended as a first-line antiretroviral regimen. Data on the efficacy of this triple nucleoside reverse transcriptase inhibitor (NRTI) combination compared wit...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2005.00315.x

    authors: Cuzin L,Pugliese P,Bugnon F,Delpierre C,Cua E,Billaud E,Massip P,Raffi F,Dellamonica P

    更新日期:2005-11-01 00:00:00

  • Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.

    abstract:OBJECTIVES:Although current guidelines recommend resistance testing prior to antiretroviral therapy (ART) reinitiation after treatment interruptions, virological failure of first-line ritonavir-boosted, protease-inhibitor (PI/r)-containing ART is associated with low emergent PI resistance. In patients experiencing unsc...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12107

    authors: Tinago W,O'Halloran JA,O'Halloran RM,Macken A,Lambert JS,Sheehan GJ,Mallon PW

    更新日期:2014-04-01 00:00:00

  • Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy.

    abstract:OBJECTIVES:Antiretroviral therapy (ART) in HIV-infected patients is associated with increased cardiovascular risk. Circulating markers of endothelial dysfunction may be used to study early atherogenesis. The aim of our study was to investigate changes in such markers during initiation of ART. METHODS:In 115 HIV-positi...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2008.00661.x

    authors: Kristoffersen US,Kofoed K,Kronborg G,Giger AK,Kjaer A,Lebech AM

    更新日期:2009-02-01 00:00:00

  • Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.

    abstract:OBJECTIVES:Whether treatment-experienced HIV-1-infected patients with an acquired K103N mutation after failing nonnucleoside reverse transcriptase inhibitor (NNRTI) regimens can be treated with rilpivirine is unknown. The aim of this pilot study was to evaluate the efficacy of rilpivirine/tenofovir/emtricitabine in HIV...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12157

    authors: Rokx C,Verbon A,Rijnders BJ

    更新日期:2014-11-01 00:00:00

  • A systematic review of risk of HIV transmission through biting or spitting: implications for policy.

    abstract:OBJECTIVES:The perceived threat of HIV transmission through spitting and biting is evidenced by the increasing use of "spit hoods" by Police Forces in the UK. In addition, a draft parliamentary bill has called for increased penalties for assaults on emergency workers, citing the risk of communicable disease transmissio...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12625

    authors: Cresswell FV,Ellis J,Hartley J,Sabin CA,Orkin C,Churchill DR

    更新日期:2018-04-23 00:00:00

  • Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects.

    abstract::An HIV-infected man presented with a pneumonic illness following an episode of treated Pneumocystis carinii pneumonia (PCP). He had a rise in his CD4 count from 4 to 125 cells/microL on antiretroviral therapy prior to the onset of the second respiratory event. Bronchoalveolar lavage (BAL) revealed no pathogen, althoug...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1468-1293.2002.00115.x

    authors: Barry SM,Lipman MC,Deery AR,Johnson MA,Janossy G

    更新日期:2002-07-01 00:00:00

  • Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study.

    abstract:OBJECTIVE:The aim of the study was to characterize and compare insulin resistance (IR) in hepatitis C virus (HCV)-antibody (Ab)-positive and HCV-Ab-negative patients with HIV infection. METHODS:This was a single-centre cross-sectional study of 1041 HIV-infected patients (373 HCV-Ab-positive; 167 with detectable plasma...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2007.00539.x

    authors: Squillace N,Lapadula G,Torti C,Orlando G,Mandalia S,Nardini G,Beghetto B,Costarelli S,Guaraldi G

    更新日期:2008-03-01 00:00:00

  • Pitfalls in measuring high-density lipoprotein cholesterol concentrations in HIV-infected patients.

    abstract:OBJECTIVES:HIV infection and its treatment are associated with dyslipidaemia and increased risk of cardiovascular disease. Accurate high-density lipoprotein (HDL) cholesterol values are necessary for the management of these abnormalities, but current methods have not been properly assessed in these patients. The aim of...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2009.00772.x

    authors: Aragonès G,Beltrán R,Rull A,Marsillach J,Rodríguez F,Alí SB,Fernández-Sender L,Camps J,Joven J,Alonso-Villaverde C

    更新日期:2010-04-01 00:00:00

  • High HIV prevalence in a southern semi-rural area of Mozambique: a community-based survey.

    abstract:BACKGROUND:Southern African countries have borne the brunt of the HIV/AIDS pandemic. Monitoring epidemiological dynamics is critical to identify the populations at greatest risk of infection and to guide control strategies. METHODS:A cross-sectional community-based study to determine age- and sex-specific HIV prevalen...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2012.01018.x

    authors: González R,Munguambe K,Aponte J,Bavo C,Nhalungo D,Macete E,Alonso P,Menéndez C,Naniche D

    更新日期:2012-11-01 00:00:00

  • Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication.

    abstract:OBJECTIVES:We evaluated the efficacy and tolerability of lamivudine + dolutegravir in a cohort of HIV-1 infected, treatment-experienced patients with undetectable HIV-RNA. METHODS:Time to treatment discontinuation (TD) and virological failure (VF) and their predictors were assessed in a multicenter cohort of HIV-1 inf...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12611

    authors: Borghetti A,Baldin G,Lombardi F,Ciccullo A,Capetti A,Rusconi S,Sterrantino G,Latini A,Cossu MV,Gagliardini R,De Luca A,Di Giambenedetto S

    更新日期:2018-03-24 00:00:00

  • Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.

    abstract:OBJECTIVES:Single nucleotide polymorphisms in the cytochrome P450 (CYP) 2B6 gene have been associated with high interindividual variation in efavirenz pharmacokinetics. However, clinical data on the relationship of CYP2B6 polymorphisms with the occurrence of efavirenz-induced central nervous system (CNS) symptoms are l...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12488

    authors: Gallien S,Journot V,Loriot MA,Sauvageon H,Morlat P,Reynes J,Reliquet V,Chêne G,Molina JM,ANRS 099 ALIZE trial study group.

    更新日期:2017-09-01 00:00:00

  • Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.

    abstract:OBJECTIVE:More and more highly treatment-experienced patients are achieving viral suppression. However, the durability of suppression remains unclear. METHODS:Patients from Royal Free Hospital (London, UK) and JW Goethe University Hospital (Frankfurt, Germany) who had failed > or = 1 antiretroviral (ARV) regimen in al...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2008.00650.x

    authors: Smith CJ,Phillips AN,Dauer B,Johnson MA,Lampe FC,Youle MS,Tyrer M,Staszewski S

    更新日期:2009-01-01 00:00:00

  • A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.

    abstract:OBJECTIVES:Low-dose stavudine therapy may have a lower toxicity profile compared with standard dose. A randomized controlled trial comparing these two doses of stavudine with tenofovir disoproxil fumarate (tenofovir DF) was performed to assess the effects on anthropometry, markers of inflammation, and lipid and glucose...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12074

    authors: Menezes CN,Crowther NJ,Duarte R,Van Amsterdam D,Evans D,Dickens C,Dix-Peek T,Rassool M,Prinsloo A,Raal F,Sanne I

    更新日期:2014-01-01 00:00:00